Literature DB >> 22198404

Parkinson disease: the controversy of levodopa toxicity in Parkinson disease.

Theresa A Zesiewicz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22198404     DOI： 10.1038/nrneurol.2011.199

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

1.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.

Authors:  O Rascol; D J Brooks; A D Korczyn; P P De Deyn; C E Clarke; A E Lang
Journal:  N Engl J Med       Date:  2000-05-18       Impact factor: 91.245

2.  Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease.

Authors:  C W Olanow; L L Gauger; J M Cedarbaum
Journal:  Ann Neurol       Date:  1991-05       Impact factor: 10.422

3.  Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.

Authors:  M G Murer; G Dziewczapolski; L B Menalled; M C García; Y Agid; O Gershanik; R Raisman-Vozari
Journal:  Ann Neurol       Date:  1998-05       Impact factor: 10.422

4.  Levodopa and the progression of Parkinson's disease.

Authors:  Stanley Fahn; David Oakes; Ira Shoulson; Karl Kieburtz; Alice Rudolph; Anthony Lang; C Warren Olanow; Caroline Tanner; Kenneth Marek
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

5.  Does levodopa accelerate the pathologic process in Parkinson disease brain?

Authors:  L Parkkinen; S S O'Sullivan; M Kuoppamäki; C Collins; C Kallis; J L Holton; D R Williams; T Revesz; A J Lees
Journal:  Neurology       Date:  2011-09-14       Impact factor: 9.910

Review 6.  Oxidative stress in Parkinson's disease.

Authors:  Peter Jenner
Journal:  Ann Neurol       Date:  2003       Impact factor: 10.422

7.  Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

Authors: 
Journal:  JAMA       Date:  2000-10-18       Impact factor: 56.272

8.  Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease.

Authors:  J P Spencer; A Jenner; J Butler; O I Aruoma; D T Dexter; P Jenner; B Halliwell
Journal:  Free Radic Res       Date:  1996-02

9.  Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.

Authors:  Jin Young Shin; Hyun-Jung Park; Young Hwan Ahn; Phil Hyu Lee
Journal:  J Neurochem       Date:  2009-09-16       Impact factor: 5.372

10.  Impact of pramipexole on the onset of levodopa-related dyskinesias.

Authors:  Radu Constantinescu; Megan Romer; Michael P McDermott; Cornelia Kamp; Karl Kieburtz
Journal:  Mov Disord       Date:  2007-07-15       Impact factor: 10.338
  10 in total
  1 in total

Review 1.  Maladaptive plasticity in levodopa-induced dyskinesias and tardive dyskinesias: old and new insights on the effects of dopamine receptor pharmacology.

Authors:  Antonio Cerasa; Alfonso Fasano; Francesca Morgante; Giacomo Koch; Aldo Quattrone
Journal:  Front Neurol       Date:  2014-04-09       Impact factor: 4.003
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.